Midatech Pharma Rallies On Positive MTX102 Results

Midatech Pharma PLC-ADR MTP shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate in diabetes.

The results showed that MTX102 was well-tolerated, with asymptomatic local injection site reactions being the only drug-related finding, and no serious adverse events were reported, according to Midatech

“This EU-funded program is an invaluable project to further develop, understand and evaluate Midatech’s gold nanoparticle technology, MidaCore,” CEO Craig Cook said in a statement.

"This is the first human study to assess the safety of MidaCore when injected into patients, and we are pleased that the data generated to date validates the technology as a potentially innovative treatment platform for medical applications." 

Midatech shares were trading higher by 45.38% at $1.89 at the time of publication Friday. The stock has a 52-week high of $10.90 and a 52-week low of $1.03.

Related Links:

Eton Pharmaceuticals Shares Slammed After FDA Complete Response Letter

Neon Therapeutics Shares Higher After Positive Cancer Vaccine Study

Posted In: DiabetesMTX102VaccinesBiotechNewsPenny StocksMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.